MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) ...

Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on Meiragtx Holdings (MGTX – Research Report). The ...

On Tuesday, MeiraGTx Holdings PLC (MGTX) stock saw a modest uptick, ending the day at $5.33 which represents a slight increase of $0.69 or 14.87% from the prior close of $4.64. The stock opened at $5.

伦敦和纽约 - 临床阶段基因医学公司MeiraGTx Holdings plc (NASDAQ:MGTX)宣布其最新临床试验MGT-GAD-025取得令人鼓舞的结果。该试验旨在治疗帕金森氏症,达到了主要的安全性和耐受性目标,同时在特发性帕金森氏症患者的关键疗效终点上也显示出显著改善。

MeiraGTx Holdings (MGTX) stock gains in premarket trading after positive trial results for the company's AAV-GAD gene therapy ...

Exciting results for MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease, with promising phase 1/2 data and ...

MeiraGTx Holdings has unveiled promising results from its clinical bridging study of AAV-GAD, a gene therapy for Parkinson’s ...

MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical-stage genetic medicines company, announced Tuesday positive top-line ...

Piper Sandler重申了对MeiraGTx Holdings plc (NASDAQ: MGTX)股票的"增持"评级，目标价保持在$26.00。 尽管股价年初至今大幅下跌，但Piper Sandler认为，鉴于公司目前约$2.43亿的企业价值和潜在的大额里程碑付款，这是投资者的一个具有吸引力的入场点。

Short interest in MeiraGTx Holdings PLC (NASDAQ:MGTX) increased during the last reporting period, rising from 1.81M to 1.95M. This put 3.49% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...